[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550799":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":35,"centralContacts":36,"locations":42,"responsibleParty":120,"collaborators":35,"id":122,"slug":35,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":35,"eligibilityCriteria":127,"healthyVolunteers":123,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":35,"studyType":134,"phases":135,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":45,"whyStopped":35,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},{"fullName":5,"class":6},"Verve Therapeutics, Inc.","INDUSTRY",[8,14,17,20,23,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: Single Ascending Dose Escalation","EXPERIMENTAL","Participants will receive a single dose of VERVE-201.",[13],"Drug: VERVE-201",{"label":15,"type":10,"description":11,"interventionNames":16},"Cohort 2: Single Ascending Dose Escalation",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"Cohort 3: Single Ascending Dose Escalation",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"Cohort 4: Single Ascending Dose Escalation",[13],{"label":24,"type":10,"description":11,"interventionNames":25},"Cohort 5: Single Ascending Dose Escalation",[13],{"label":27,"type":10,"description":11,"interventionNames":28},"Cohort 6: Single Ascending Dose Escalation",[13],[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","VERVE-201","Intravenous (IV) infusion",[9,15,18,21,24,27],null,[37],{"name":38,"role":39,"phone":40,"phoneExt":35,"email":41},"Clinical Development","CONTACT","781-970-6833","verve201clinicaltrials@lists.lilly.com",[43,54,61,69,76,83,91,98,106,113],{"facility":44,"status":45,"city":46,"state":35,"zip":35,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":35},"Clinical Study Center","RECRUITING","Adelaide","Australia",{"type":49,"coordinates":50},"Point",[51,52],138.59863,-34.92866,{"lat":52,"lon":51},{"facility":44,"status":45,"city":55,"state":35,"zip":35,"country":47,"cosmosGeoPoint":56,"geoPoint":60,"contacts":35},"Melbourne",{"type":49,"coordinates":57},[58,59],144.96332,-37.814,{"lat":59,"lon":58},{"facility":44,"status":45,"city":62,"state":35,"zip":35,"country":63,"cosmosGeoPoint":64,"geoPoint":68,"contacts":35},"Chicoutimi","Canada",{"type":49,"coordinates":65},[66,67],-71.06369,48.41963,{"lat":67,"lon":66},{"facility":44,"status":45,"city":70,"state":35,"zip":35,"country":63,"cosmosGeoPoint":71,"geoPoint":75,"contacts":35},"Montreal",{"type":49,"coordinates":72},[73,74],-73.58781,45.50884,{"lat":74,"lon":73},{"facility":44,"status":45,"city":77,"state":35,"zip":35,"country":63,"cosmosGeoPoint":78,"geoPoint":82,"contacts":35},"Toronto",{"type":49,"coordinates":79},[80,81],-79.39864,43.70643,{"lat":81,"lon":80},{"facility":44,"status":45,"city":84,"state":35,"zip":35,"country":85,"cosmosGeoPoint":86,"geoPoint":90,"contacts":35},"Cape Town","South Africa",{"type":49,"coordinates":87},[88,89],18.42322,-33.92584,{"lat":89,"lon":88},{"facility":44,"status":45,"city":92,"state":35,"zip":35,"country":85,"cosmosGeoPoint":93,"geoPoint":97,"contacts":35},"Johannesburg",{"type":49,"coordinates":94},[95,96],28.04363,-26.20227,{"lat":96,"lon":95},{"facility":44,"status":45,"city":99,"state":35,"zip":35,"country":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":35},"Liverpool","United Kingdom",{"type":49,"coordinates":102},[103,104],-2.97794,53.41058,{"lat":104,"lon":103},{"facility":44,"status":45,"city":107,"state":35,"zip":35,"country":100,"cosmosGeoPoint":108,"geoPoint":112,"contacts":35},"London",{"type":49,"coordinates":109},[110,111],-0.12574,51.50853,{"lat":111,"lon":110},{"facility":44,"status":45,"city":114,"state":35,"zip":35,"country":100,"cosmosGeoPoint":115,"geoPoint":119,"contacts":35},"Manchester",{"type":49,"coordinates":116},[117,118],-2.23743,53.48095,{"lat":118,"lon":117},{"type":121,"investigatorFullName":35,"investigatorTitle":35,"investigatorAffiliation":35,"oldNameTitle":35,"oldOrganization":35},"SPONSOR","100550799",false,"NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia","A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia","Inclusion Criteria:\n\n* Refractory hypercholesterolemia\n* Refractory hypertriglyceridemia\n\nExclusion Criteria:\n\n* Active or history of chronic liver disease\n* Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":132,"type":133},36,"ESTIMATED","INTERVENTIONAL",[136],"PHASE1","VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.\n\nVERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.",[139,140,141],"Hypercholesterolemia","Hypertriglyceridemia","Refractory Hyperlipidemia",[32,143,144,145,146,147,148,141,149],"Gene Editing","Base Editing","Refractory Hypercholesterolemia","ANGPTL3","ASCVD","Refractory Hypertriglyceridemia","Familial Hypercholesterolemia","2026-04-22",{"date":152,"type":153},"2026-04-28","ACTUAL",{"date":155,"type":153},"2024-10-30",{"date":157,"type":133},"2027-12",{"name":5,"class":6},10]